Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 15/20 | 0.66 |
| ▸ | CCKAR | P32238 | 5/20 | 0.61 |
| ▸ | CCKBR | P32239 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28759734 | 1.00 | CBLB (0.66) | CBLBCCKARCCKBR | |
| SCHEMBL3823264 | 0.92 | CCKBR (0.64) | CBLBCCKARCCKBR | |
| SCHEMBL3823262 | 0.92 | CCKBR (0.64) | CBLBCCKARCCKBR | |
| SCHEMBL3824296 | 0.90 | CBLB (0.75) | CBLBCCKARCCKBR | |
| SCHEMBL3825368 | 0.90 | CCKBR (0.64) | CBLBCCKARCCKBR | |
| SCHEMBL3825363 | 0.90 | CCKBR (0.64) | CBLBCCKARCCKBR | |
| SCHEMBL3823478 | 0.89 | CCKBR (0.61) | CBLBCCKARCCKBR | |
| SCHEMBL24611933 | 0.87 | CBLB (0.53) | CBLBCCKARCCKBR | |
| SCHEMBL20867277 | 0.87 | CBLB (0.53) | CBLBCCKARCCKBR | |
| SCHEMBL3822831 | 0.85 | CCKBR (0.64) | CBLBCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | claimed |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-06-12 | — | — | US | claimed |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | claimed |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-08-09 | — | — | US | claimed |
| EP-1740185-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING RSV INFECTION | Arrow Therapeutics Limited (GB) | 2007-01-10 | — | — | EP | claimed |
| WO-2005089770-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| EP-1740185-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING RSV INFECTION | Arrow Therapeutics Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| EP-1727551-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005089770-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | CBLB 3827/4885CCKAR 2354/4885CCKBR 2243/4885 |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | CNR1, SIGMAR1, GABRA3 | CBLB 2588/4885CCKAR 114/4885CCKBR 246/4885 |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | CNR1, CBR1, CBR3 | CBLB 3122/4885CCKAR 185/4885CCKBR 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.